These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15912960)

  • 41. Cathepsin W expressed exclusively in CD8+ T cells and NK cells, is secreted during target cell killing but is not essential for cytotoxicity in human CTLs.
    Stoeckle C; Gouttefangeas C; Hammer M; Weber E; Melms A; Tolosa E
    Exp Hematol; 2009 Feb; 37(2):266-75. PubMed ID: 19100676
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules.
    Shen L; Rock KL
    Curr Opin Immunol; 2006 Feb; 18(1):85-91. PubMed ID: 16326087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generation of endostatin by matrix metalloproteinase and cathepsin from human limbocorneal epithelial cells cultivated on amniotic membrane.
    Ma DH; Yao JY; Kuo MT; See LC; Lin KY; Chen SC; Chen JK; Chao AS; Wang SF; Lin KK
    Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):644-51. PubMed ID: 17251461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid-mediated presentation of MHC class II molecules guides thymocytes to the CD4 lineage.
    Komaniwa S; Hayashi H; Kawamoto H; Sato SB; Ikawa T; Katsura Y; Udaka K
    Eur J Immunol; 2009 Jan; 39(1):96-112. PubMed ID: 19089815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MHC class II-mediated antigen presentation by alloreactive rat CD4+ T cells does not induce regulatory properties.
    Otto C; Heeg A; Kottenmeier S; Tiurbe GC; Thiede A; Ulrichs K
    Transplant Proc; 2006 Apr; 38(3):755-6. PubMed ID: 16647463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lysosomal cysteine proteases: structure, function and inhibition of cathepsins.
    Roberts R
    Drug News Perspect; 2005 Dec; 18(10):605-14. PubMed ID: 16491162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Application of a novel highly sensitive activity-based probe for detection of cathepsin G.
    Zou F; Schmon M; Sienczyk M; Grzywa R; Palesch D; Boehm BO; Sun ZL; Watts C; Schirmbeck R; Burster T
    Anal Biochem; 2012 Feb; 421(2):667-72. PubMed ID: 22178917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages.
    Thanei S; Theron M; Silva AP; Reis B; Branco L; Schirmbeck L; Kolb FA; Haap W; Schindler T; Trendelenburg M
    Biochem Pharmacol; 2017 Dec; 146():151-164. PubMed ID: 28987592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo.
    Shen L; Sigal LJ; Boes M; Rock KL
    Immunity; 2004 Aug; 21(2):155-65. PubMed ID: 15308097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cathepsin S: therapeutic, diagnostic, and prognostic potential.
    Wilkinson RD; Williams R; Scott CJ; Burden RE
    Biol Chem; 2015 Aug; 396(8):867-82. PubMed ID: 25872877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Phosphoinositide Kinase PIKfyve Promotes Cathepsin-S-Mediated Major Histocompatibility Complex Class II Antigen Presentation.
    Baranov MV; Bianchi F; Schirmacher A; van Aart MAC; Maassen S; Muntjewerff EM; Dingjan I; Ter Beest M; Verdoes M; Keyser SGL; Bertozzi CR; Diederichsen U; van den Bogaart G
    iScience; 2019 Jan; 11():160-177. PubMed ID: 30612035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacodynamic Monitoring of RO5459072, a Small Molecule Inhibitor of Cathepsin S.
    Theron M; Bentley D; Nagel S; Manchester M; Gerg M; Schindler T; Silva A; Ecabert B; Teixeira P; Perret C; Reis B
    Front Immunol; 2017; 8():806. PubMed ID: 28769925
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cysteine cathepsin activity regulation by glycosaminoglycans.
    Novinec M; Lenarčič B; Turk B
    Biomed Res Int; 2014; 2014():309718. PubMed ID: 25587532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics.
    Brown R; Nath S; Lora A; Samaha G; Elgamal Z; Kaiser R; Taggart C; Weldon S; Geraghty P
    Respir Res; 2020 May; 21(1):111. PubMed ID: 32398133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of a Highly Selective Cathepsin S Two-step Activity-Based Probe in Multicolor Bio-Orthogonal Correlative Light-Electron Microscopy.
    van Dalen FJ; Bakkum T; van Leeuwen T; Groenewold M; Deu E; Koster AJ; van Kasteren SI; Verdoes M
    Front Chem; 2020; 8():628433. PubMed ID: 33644004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bacterial toxins as immunomodulators.
    Donaldson DS; Williams NA
    Adv Exp Med Biol; 2009; 666():1-18. PubMed ID: 20054971
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cathepsin S as a cancer target.
    Zhang L; Wang H; Xu J
    Neoplasma; 2015; 62(1):16-26. PubMed ID: 25563363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PP2A: A Novel Target to Prevent Cathepsin S-mediated Damage in Smoking-induced Chronic Obstructive Pulmonary Disease.
    Janga SR; Hamm-Alvarez SF
    Am J Respir Crit Care Med; 2019 Jul; 200(1):6-8. PubMed ID: 30785780
    [No Abstract]   [Full Text] [Related]  

  • 59. [Evidence of the complex nature of cathepsin and contribution to the cleaning of a component (cathepsin T)].
    LANG K; WEGNER E
    Biochem Z; 1948; 318(4-5):462-71. PubMed ID: 18887944
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.
    Payne CD; Deeg MA; Chan M; Tan LH; LaBell ES; Shen T; DeBrota DJ
    Br J Clin Pharmacol; 2014 Dec; 78(6):1334-42. PubMed ID: 25039273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.